Clinical Trials for Guardant Health

Explore 12 clinical trials worldwide

Showing 1-12 of 12 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Guardant Health

Clinical Trials (12)

NCT07004413
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
PHASE3Not yet recruiting
267 participants
Started: Jan 1, 2026 · Completed: Jan 1, 2031
1 condition3 sponsors1 location
NCT06880055
Shield Post-Approval Study Protocol
N/ARecruiting
3,375 participants
Started: Jul 14, 2025 · Completed: Dec 1, 2030
1 condition1 sponsor1 location
NCT06444542
Understanding Patient Preference on Colorectal Cancer Screening Options-PSU
N/ARecruiting
900 participants
Started: Sep 16, 2024 · Completed: Dec 31, 2026
1 condition4 sponsors1 location
NCT05935384
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
N/ARecruiting
470 participants
Started: Oct 25, 2023 · Completed: Dec 30, 2030
3 conditions1 sponsor1 location
NCT05885009
Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)
N/ARecruiting
240 participants
Started: Mar 28, 2023 · Completed: Mar 28, 2028
1 condition7 sponsors1 location
NCT05117840
Screening for High Frequency Malignant Disease
N/AActive, not recruiting
12,000 participants
Started: Jan 13, 2022 · Completed: Dec 31, 2025
1 condition1 sponsor143 locations
NCT05059444
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
N/ARecruiting
2,020 participants
Started: Sep 7, 2021 · Completed: Aug 31, 2029
16 conditions1 sponsor57 locations
NCT04497285
Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer
N/AActive, not recruiting
600 participants
Started: Oct 20, 2020 · Completed: Nov 30, 2026
1 condition4 sponsors1 location
NCT04410796
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
PHASE2Recruiting
571 participants
Started: May 28, 2020 · Completed: May 31, 2026
1 condition3 sponsors18 locations
NCT04087473
Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC
N/ARecruiting
50 participants
Started: Aug 23, 2019 · Completed: Dec 31, 2025
2 conditions2 sponsors5 locations
NCT03774758
Biomarkers for Risk Stratification in Lung Cancer
N/ARecruiting
590 participants
Started: Dec 17, 2017 · Completed: Dec 31, 2025
2 conditions3 sponsors3 locations
NCT03791034
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
N/ARecruiting
700 participants
Started: Aug 28, 2017 · Completed: Dec 31, 2026
1 condition2 sponsors1 location